

Accepted Manuscript

Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics

Rajnee Kanwal, Sanjeev Shukla, Ethan Walker, Sanjay Gupta



PII: S0304-3835(18)30339-2

DOI: [10.1016/j.canlet.2018.05.014](https://doi.org/10.1016/j.canlet.2018.05.014)

Reference: CAN 13898

To appear in: *Cancer Letters*

Received Date: 3 April 2018

Revised Date: 8 May 2018

Accepted Date: 10 May 2018

Please cite this article as: R. Kanwal, S. Shukla, E. Walker, S. Gupta, Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics, *Cancer Letters* (2018), doi: 10.1016/j.canlet.2018.05.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Abstract

The role of CD133 (Prominin-1) as a cancer stem cell marker may be useful for therapeutic approaches and prognostication in prostate cancer patients. We investigated the stem-cell-related function and biological features of a subpopulation of CD133⁺ cells isolated from established primary human prostate cancer cell lines. The CD133⁺ cells sorted from human prostate cancer 22Rv1 exhibited high clonogenic and tumorigenic capabilities, sphere forming capacity and serially reinitiated transplantable tumors in NOD-SCID mice. Gene profiling analysis of CD133⁺ cells showed upregulation of markers of stem cell differentiation (CD44, Oct4, SOX9 and Nanog), epithelial-to-mesenchymal transition (c-myc and BMI1), osteoblastic differentiation (Runx2), and skeletal morphogenesis (BMP2), compared to side population of CD133⁻ cells. These cells are highly malignant and resistant to γ -radiation and chemotherapeutic drug, docetaxel. Importantly, a docetaxel-resistant subclone was more enriched in CD133⁺ cells with significant increase in Runx2 expression, compared to CD133⁻ cells. Furthermore, knockdown of Runx2 in these cells resulted in differential response to chemotherapy, sensitizing them to increased cell death. These results demonstrate therapy-resistant population with stem-like features are distinct subpopulation of malignant cells that resides within parental cell lines. The molecular signature of CD133⁺ cells may lead to identification of novel therapeutic targets and prognostic markers in the treatment of prostate cancer.

Download English Version:

<https://daneshyari.com/en/article/8434265>

Download Persian Version:

<https://daneshyari.com/article/8434265>

[Daneshyari.com](https://daneshyari.com)